Literature DB >> 34981772

Crystal structure of a putative short-chain dehydrogenase/reductase from Paraburkholderia xenovorans.

Jaysón Davidson1, Kyndall Nicholas1, Jeremy Young1, Deborah G Conrady2, Stephen Mayclin2, Sandhya Subramanian3, Bart L Staker3, Peter J Myler3, Oluwatoyin A Asojo1.   

Abstract

Paraburkholderia xenovorans degrades organic wastes, including polychlorinated biphenyls. The atomic structure of a putative dehydrogenase/reductase (SDR) from P. xenovorans (PxSDR) was determined in space group P21 at a resolution of 1.45 Å. PxSDR shares less than 37% sequence identity with any known structure and assembles as a prototypical SDR tetramer. As expected, there is some conformational flexibility and difference in the substrate-binding cavity, which explains the substrate specificity. Uniquely, the cofactor-binding cavity of PxSDR is not well conserved and differs from those of other SDRs. PxSDR has an additional seven amino acids that form an additional unique loop within the cofactor-binding cavity. Further studies are required to determine how these differences affect the enzymatic functions of the SDR. open access.

Entities:  

Keywords:  Paraburkholderia xenovorans; SSGCID; Seattle Structural Genomics Center for Infectious Disease; detoxification; education and training; oxidoreductases; structural genomics

Mesh:

Substances:

Year:  2022        PMID: 34981772      PMCID: PMC8725002          DOI: 10.1107/S2053230X21012632

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


Introduction

Paraburkholderia xenovorans is a model bacterium used to study unique pathways, notably the ability of this genus of bacteria to degrade polychlorinated biphenyls and other organic waste products (Francova et al., 2004 ▸; Tehrani et al., 2014 ▸). The genome of P. xenovorans has been sequenced and is one of the largest bacterial genomes studied to date. P. xenovorans has diverse functions, including nitrogen fix­ation, the catabolysis of aromatic compounds and the degradation of various organic wastes (Francova et al., 2004 ▸; Tehrani et al., 2014 ▸). However, the underlying mechanisms of many of these processes are poorly understood. Additionally, unlike some other Paraburkholderia species, P. xenovorans is not pathogenic to humans. The Seattle Structural Genomics Center for Infectious Disease (SSGCID) selected targets from P. xenovorans for high-throughput structural studies to increase the breadth of drug-target structures to aid drug development against human pathogenic Burkholderia species such as B. mallei and B. pseudomallei. Here, we present the structure of one of these target proteins, a short-chain de­hydrogenase/reductase (SDR) which shares less than 37% sequence identity with any published structure. P. xenovorans SDR (PxSDR) is predicted to be a type II fatty-acid synthetase and NAD(P)(H)-dependent oxidoreductase involved in the metabolism of diverse molecules, including lipids, amino acids, carbohydrates, cofactors, hormones and xenobiotics, or other compounds. The structure reported here may offer insights into the metabolism of small molecules by P. xenovorans.

Materials and methods

Macromolecule production

Cloning, expression and purification were conducted as part of the Seattle Structural Genomics Center for Infectious Disease (SSGCID; Myler et al., 2009 ▸; Stacy et al., 2011 ▸) following standard protocols described previously (Bryan et al., 2011 ▸; Choi et al., 2011 ▸; Serbzhinskiy et al., 2015 ▸). The full-length putative short-chain reductase (PxSDR, UniProt Q13GE3) was PCR-amplified from genomic DNA using the primers shown in Table 1 ▸. The resultant amplicon was cloned into the ligation-independent cloning (LIC; Aslanidis & de Jong, 1990 ▸) expression vector pBG1861 encoding a non­cleavable 6×His fusion tag (MAHHHHHHM-ORF). Plasmid DNA was transformed into chemically competent Escherichia coli BL21(DE3)R3 Rosetta cells. The plasmid containing His-PxSDR was expression-tested and 2 l of culture was grown using auto-induction medium (Studier, 2005 ▸) in a LEX Bio­reactor (Epiphyte Three Inc.). The expression clone for PxSDR, BuxeA.00010.c.B1.GE39410, is available at https://www.ssgcid.org/available-materials/expression-clones/.
Table 1

Macromolecule-production information

Source organism Paraburkholderia xenovorans (strain LB400)
DNA sourceGenomic DNA, provided by Dr Mary Lidstrom (University of Washington, USA)
Forward primer5′-CTCACCACCACCACCACCATATGAGTTCAGCAGGAAGATTGCAG-3′
Reverse primer5′-ATCCTATCTTACTCACTTAATCGCAGCGGGCGCTCATCC-3′
Expression vectorpBG1861
Expression host Escherichia coli BL21(DE3)R3 Rosetta cells
Complete amino-acid sequence of the construct producedMAHHHHHHMSSAGRLQGKVALVTGAGCIGPGWGNGRAIAVRFAEEGAHVIAVDRDLASMDATLELVRAAGGSVTPCLCDVTDSASVERLVADSVARCGRVDILVNNVGAPSPGGPVALDEAQWAMQLELNLTTAFLMCKYVLPVMEQQGGGAIVNIASTSGIRWTGAAQVGYAAAKAGMIQMGRVVAVEYAAKNVRVNSVVPGLLHTPMVDTKIAHNQAGGDVELLLRKRQARIPMPFMGDGRDTANAALFLASDEARFVTGTEIVVDGGMSARCD
His-PxSDR was purified in a two-step protocol consisting of an immobilized metal-affinity chromatography (IMAC) step and size-exclusion chromatography (SEC). All chromatography runs were performed on an ÄKTApurifier 10 (GE) using automated IMAC and SEC programs according to previously described procedures (Bryan et al., 2011 ▸). Thawed bacterial pellets were lysed by sonication in 200 ml buffer consisting of 25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 0.5% CHAPS, 30 mM imidazole, 10 mM MgCl2, 1 mM TCEP, 250 µg ml−1 AEBSF, 0.025% azide. After sonication, the crude lysate was clarified with 20 µl (25 units µl−1) benzonase and incubated while mixing at room temperature for 45 min. The lysate was then clarified by centrifugation at 10 000 rev min−1 for 1 h using a Sorvall centrifuge (Thermo Scientific). The clarified supernatant was then passed over an Ni–NTA HisTrap FF 5 ml column (GE Healthcare) which was pre-equilibrated with loading buffer composed of 25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 30 mM imidazole, 1 mM TCEP, 0.025% sodium azide. The column was washed with 20 column volumes (CV) of loading buffer and was eluted with loading buffer plus 250 mM imidazole in a linear gradient over 7 CV. Peak fractions, as determined by UV absorption at 280 nm, were pooled and concentrated to 5 ml. A SEC column (Superdex 75, GE) was equilibrated with running buffer composed of 25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 2 mM DTT, 0.025% azide. The peak fractions were collected and analyzed for the protein of interest using SDS–PAGE. The SEC peak fractions eluted as a single large peak at a molecular mass of ∼76 kDa, suggesting a dimeric enzyme. The peak fractions were pooled and concentrated to 45 mg ml−1 using an Amicon purification system (Millipore). Aliquots of 200 µl were flash-frozen in liquid nitrogen and stored at −193 K until use for crystallization.

Crystallization

PxSDR was crystallized by the sitting-drop vapor-diffusion method using the JCSG+ commercial crystallization screen (Rigaku Reagents). Crystals were obtained by mixing 0.4 µl protein solution at 22.5 mg ml−1 with 0.4 µl precipitant (Rigaku Reagents JCSG+ screen condition H11: 0.2 M magnesium chloride, 0.1 M bis-Tris pH 5.5, 25% PEG 3350), equilibrating against a reservoir consisting of 80 µl precipitant and incubating at 287 K (Table 2 ▸). A single crystal was transferred into a cryoprotectant (reservoir solution supplemented with 20% ethylene glycol) and vitrified by plunging into liquid nitrogen before data collection.
Table 2

Crystallization

MethodVapor diffusion, sitting drop
Plate type96-well, Compact 300, Rigaku
Temperature (K)287
Protein concentration PxSDR (BuxeA.00010.c.B1.PS02595) at 22.5 mg ml−1
Buffer composition of protein solution25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 2 mM DTT, 0.025% azide
Composition of reservoir solutionRigaku Reagents JCSG+ screen H11: 0.2 M magnesium chloride, 0.1 M bis-Tris pH 5.5, 25% PEG 3350
Volume and ratio of drop0.4 µl protein:0.4 µl reservoir (1:1)
Volume of reservoir (µl)80

Data collection and processing

X-ray diffraction data were collected on LS-CAT beamline 21-ID-F at the Advanced Photon Source. Data were integrated using XDS and reduced with XSCALE (Kabash, 2010 ▸). Additional data-collection information is provided in Table 3 ▸. The raw images and detailed data-collection information are available for download (https://proteindiffraction.org/project/5jc8/).
Table 3

Data collection and processing

Values in parentheses are for the outer shell.

Diffraction sourceBeamline 21-ID-F, APS
Wavelength (Å)0.97872
Temperature (K)100
DetectorRayoniX MX-225 CCD
Crystal-to-detector distance (mm)140
Rotation range per image (°)1
Total rotation range (°)240
Exposure time per image (s)1
Space group P21
a, b, c (Å)71.18, 81.08, 86.37
α, β, γ (°)90, 94.53, 90
Mosaicity (°)0.145
Resolution range (Å)50–1.45 (1.49–1.45)
Total No. of reflections855886 (53861)
No. of unique reflections165687 (10796)
Completeness (%)95.8 (84.8)
Multiplicity5.2 (5.0)
I/σ(I)〉25.10 (4.45)
R r.i.m. 0.042 (0.392)
Overall B factor from Wilson plot (Å2)12.76

Estimated R r.i.m. = R merge[N/(N − 1)]1/2, where N is the data multiplicity.

Structure solution and refinement

The structure of PxSDR was solved by molecular replacement with MOLREP (Vagin & Teplyakov, 2010 ▸; Lebedev et al., 2008 ▸) using PDB entry 4ni5 (36% sequence identity), an unpublished structure from the SSGCID, as a search model. The structure was refined in Phenix (Liebschner et al., 2010 ▸) with manual model building in Coot (Emsley & Cowtan, 2004 ▸; Emsley et al., 2010 ▸). The quality of the model was assessed using MolProbity (Headd et al., 2009 ▸) and structure-refinement statistics are provided in Table 4 ▸. The structure was deposited in the Protein Data Bank as entry 5jc8. All structure figures were made using PyMOL (DeLano, 2002 ▸).
Table 4

Structure solution and refinement

Values in parentheses are for the outer shell

Resolution range (Å)50–1.45 (1.48–1.45)
Completeness (%)95.8
σ Cutoff F > 1.34σ(F)
No. of reflections, working set165652 (9476)
No. of reflections, test set2032 (112)
Final R cryst 0.141 (0.194)
Final R free 0.158 (0.202)
No. of non-H atoms
 Protein7374
 Ion4
 Ligand66
 Solvent1068
 Total8512
R.m.s. deviations
 Bonds (Å)0.007
 Angles (°)0.878
Average B factors (Å2)
 Protein17.5
 Ion17.7
 Ligand33.7
 Water31.7
Ramachandran plot
 Most favored (%)96
 Allowed (%)4

Results and discussion

The reported apo structure of PxSDR was determined in the monoclinic space group P21 as a prototypical SDR tetramer (Fig. 1 ▸). Each monomer has the prototypical NADPH Rossmann topology as observed in the architecture of PFAM domain PF00106 or the short-chain dehydrogenases. Specifically, PxSDR has the enoyl-(acyl carrier protein) reductase or 3-oxoacyl-ACP reductase domain architecture otherwise referred to as adh_short_C2. The most similar structures to PxSDR were identified by PDBeFold (http://www.ebi.ac.uk/msd-srv/ssm) analysis using the default threshold cutoffs of 70% for the percentage of secondary structure of the target chain identified in the query protein and of the secondary structure of the query chain (Krissinel & Henrick, 2004 ▸). The closest structure is that of the ketone reductase ChKRED20 from the genome of Chryseobacterium (Li et al., 2019 ▸). This enzyme shares a sequence identity of <36%, with an r.m.s.d. of 1.24 Å for 89% of the matched sequence identity. Wild-type ChKRED20 is an NADH-dependent ketoreductase that reduces over 100 g l−1 ketones for some pharmaceutically relevant substrates and can use 2-propanol as the ultimate reducing agent. All of the closest structures have less than 36% sequence similarity to PxSDR (Fig. 2 ▸). These structures are PDB entry 1iy8, the crystal structure of levodione reductase from Leifsonia aquatica (Sogabe et al., 2003 ▸), PDB entry 3ftp, a 3-ketoacyl-(acyl-carrier-protein) reductase from Burkholderia pseudomallei (Baugh et al., 2013 ▸), PDB entry 6t6n, Klebsiella pneumoniae FabG2(NADH-dependent) in complex with NADH (Vella et al., 2021 ▸), and PDB entry 6ixm, ketone reductase ChKRED20 from the genome of Chryseobacterium (Li et al., 2019 ▸). Interestingly, while all of the other structures have well conserved cofactor-binding domains, an extended loop connecting the first strand in the N-terminus to the first helix creates a larger cofactor-binding cavity in PxSDR (Figs. 2 ▸ and 3 ▸). This additional structural difference between PxSDR and the other structures in the cofactor-binding domain is unique. This is an unexpected difference between PxSDR and the other proteins beyond the expected flexibility in proximity to the substrate-binding cavity. While the flexibility in the substrate-binding cavity explains the specificity of each protein, it is unknown why PxSDR has this unique insertion in the cofactor loop (Figs. 2 ▸ and 3 ▸).
Figure 1

PxSDR is a prototypyical SDR tetramer.

Figure 2

Structural and primary-sequence alignment of PxSDR with the closest structures identified by PDBeFold. Also shown is the percent identity matrix generated with Clustal2.1. The structures are PDB entry 5jc8 (the apo structure of PxSDR), PDB entry 1iy8 (the crystal structure of levodione reductase from Leifsonia aquatica), PDB entry 3ftp [3-ketoacyl-(acyl-carrier-protein) reductase from Burkholderia pseudomallei], PDB entry 6t6n [Klebsiella pneumoniae FabG2(NADH-dependent) in complex with NADH] and PDB entry 6ixm (ketone reductase ChKRED20 from the genome of Chryseobacterium). The secondary-structure elements shown are α-helices (α), 310-helices (η), β-strands (β) and β-turns (TT). Identical residues are shown in white on a red background and conserved residues are shown in red. This figure was generated using ESPript (Gouet et al., 1999 ▸, 2003 ▸).

Figure 3

PxSDR superposed on its closest structural orthologues reveals differences in the substrate- and cofactor-binding cavities. (a) The substrate-binding cavities of the proteins, indicated in the blue circle, have differences that are indicative of different substrate specificities. (b) PxSDR in black has a unique loop insertion in the cofactor-binding cavity, while the other proteins have a well conserved cofactor-binding cavity and loops. The superposed structures are PDB entry 5jc8 (apo structure of PxSDR, black), PDB entry 1iy8 (crystal structure of levodione reductase from Leifsonia aquatica, red), PDB entry 3ftp [3-ketoacyl-(acyl-carrier-protein) reductase from Burkholderia pseudomallei, yellow], PDB entry 6t6n [Klebsiella pneumoniae FabG2(NADH-dependent) in complex with NADH, wheat] and PDB entry 6ixm (ketone reductase ChKRED20 from the genome of Chryseobacterium, aquamarine). The cofactor, NADH and substrate, (4R)-2-methylpentane-2,4-diol, are from PDB entry 1iy8. Structures were superposed with PyMOL.

Conclusions

While having a prototypical SDR topology, the apo structure of PxSDR reveals conformational flexibility in both the cofactor- and substrate-binding cavities that needs to be further investigated in order to determine the roles of this enzyme in the degradation of organic wastes by P. xenovorans. PDB reference: putative short-chain reductase, 5jc8
  21 in total

1.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

2.  A FabG inhibitor targeting an allosteric binding site inhibits several orthologs from Gram-negative ESKAPE pathogens.

Authors:  Peter Vella; Reshma Srilakshmi Rudraraju; Thomas Lundbäck; Hanna Axelsson; Helena Almqvist; Michaela Vallin; Gunter Schneider; Robert Schnell
Journal:  Bioorg Med Chem       Date:  2020-12-05       Impact factor: 3.641

3.  Structure-guided engineering of ChKRED20 from Chryseobacterium sp. CA49 for asymmetric reduction of aryl ketoesters.

Authors:  Tong-Biao Li; Feng-Jiao Zhao; Zhongchuan Liu; Yun Jin; Yan Liu; Xiao-Qiong Pei; Zhi-Gang Zhang; Ganggang Wang; Zhong-Liu Wu
Journal:  Enzyme Microb Technol       Date:  2019-03-04       Impact factor: 3.493

4.  Protein production by auto-induction in high density shaking cultures.

Authors:  F William Studier
Journal:  Protein Expr Purif       Date:  2005-05       Impact factor: 1.650

5.  Ability of bacterial biphenyl dioxygenases from Burkholderia sp. LB400 and Comamonas testosteroni B-356 to catalyse oxygenation of ortho-hydroxychlorobiphenyls formed from PCBs by plants.

Authors:  K Francova; M Macková; T Macek; M Sylvestre
Journal:  Environ Pollut       Date:  2004       Impact factor: 8.071

6.  Immobilized metal-affinity chromatography protein-recovery screening is predictive of crystallographic structure success.

Authors:  Ryan Choi; Angela Kelley; David Leibly; Stephen Nakazawa Hewitt; Alberto Napuli; Wesley Van Voorhis
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-08-13

7.  High-throughput protein production and purification at the Seattle Structural Genomics Center for Infectious Disease.

Authors:  Cassie M Bryan; Janhavi Bhandari; Alberto J Napuli; David J Leibly; Ryan Choi; Angela Kelley; Wesley C Van Voorhis; Thomas E Edwards; Lance J Stewart
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-08-13

8.  Autofix for backward-fit sidechains: using MolProbity and real-space refinement to put misfits in their place.

Authors:  Jeffrey J Headd; Robert M Immormino; Daniel A Keedy; Paul Emsley; David C Richardson; Jane S Richardson
Journal:  J Struct Funct Genomics       Date:  2008-11-11

9.  Combining functional and structural genomics to sample the essential Burkholderia structome.

Authors:  Loren Baugh; Larry A Gallagher; Rapatbhorn Patrapuvich; Matthew C Clifton; Anna S Gardberg; Thomas E Edwards; Brianna Armour; Darren W Begley; Shellie H Dieterich; David M Dranow; Jan Abendroth; James W Fairman; David Fox; Bart L Staker; Isabelle Phan; Angela Gillespie; Ryan Choi; Steve Nakazawa-Hewitt; Mary Trang Nguyen; Alberto Napuli; Lynn Barrett; Garry W Buchko; Robin Stacy; Peter J Myler; Lance J Stewart; Colin Manoil; Wesley C Van Voorhis
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Model preparation in MOLREP and examples of model improvement using X-ray data.

Authors:  Andrey A Lebedev; Alexei A Vagin; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.